A new biosimilar has been approved by FDA, for the treatment of macular degeneration and other eye diseases. This approval has sent positive waves in the medical community because with this new remedy the macular degeneration can be treated on a more wide scale.
To know about this breathtaking achievement, let us first learn about this disease.
What is Macular Degeneration?
Macular degeneration is a common eye disorder. According to the doctors of the best hospitals in Lahore, macular degeneration is most of the time due to older age.
In this medical condition mostly the central vision is affected. Loss of central vision means that the person is unable to see what is in front of them when they are looking ahead.
Macular degeneration is not associated with complete loss of vision. It does not affect your peripheral vision. We are able to see the things that are on the sides. This condition does not affect the ability of a person. But this condition if left untreated can cause complete loss of vision in people.
Symptoms of Macular Degeneration
This disease does not cause a loss of vision all of a sudden. Rather it progresses slowly and then gets worse with the passage of time.
Furthermore, the signs and symptoms of macular degeneration are not apparent at the start. People may have it and may not know about it. Given below are some of the common symptoms of this medical condition.
- Reduced central vision
- Straight lines are highly distorted in the line of sight
- Less adaptability to low lights
- Need of brighter light even during daytime
- Blurred visions
- Damaged retinas
- Difficulty in recognizing even familiar faces
Types of Macular Degeneration
There are two well-known types of macular degeneration
- Dry macular degeneration
- Wet macular degeneration
Dry macular degeneration
It is a common disorder of the eyes. This condition is more apparent in people who are over 50 years old. Due to the constant thinning of the macula, the inner lining of the retina, the central vision is heavily affected. This leads to distorted or blurred vision. This condition can affect both or one eye.
Wet Macular Degeneration
Wet macular degeneration is a rare medical condition in which the person suffers from blurred vision. This condition is mostly due to the presence of abnormal blood vessels which causes either the leakage of fluid or blood in the macula. Your central vision mainly depends upon the macula. So when the macula is unable to work properly, the vision is disturbed.
What is a Biosimilar?
Biosimilar is a drug that is in sync with its pricer parent drug. Most of the time, the derivation of these products is from a biological organism such as bacteria or yeast. Biosimilar are those drugs that are approved by the FDA. The collection of data plays the main role. When the biologically derived product is similar to the reference product the biosimilar is good to go to the market.
With biosimilar, patients can expect the same efficiency that they were getting from the reference product. The main difference is that in contrast to the expensive drug that has been patented this biosimilar is actually quite cost-effective.
The Approval of Biosimilar
In a press release, FDA highlighted the prominent features of this biosimilar. The data that was gathered from several time reviews gave the green light for approval. From extensive structural characterization to efficient usage which also included the better immune response, all these things pointed out that Byooviz is biosimilar to Lucentis.
The FDA further stated that this approval will set a milestone in treating the disease that has been the leading cause of vision loss in millions of people. This also proves that the FDA is committed to its role in providing nothing but the best treatment procedures so that the onset of this disease can be minimized.
Macular degeneration is a major cause of the loss of vision. With the help of this biosimilar, the disease can be controlled to a great extent. The usage and dose requirements are more or less the same as the reference products. But due to its derivation from biological products this biosimilar will treat a wide range of patients.